IMR Press / FBL / Volume 8 / Issue 5 / DOI: 10.2741/992

Frontiers in Bioscience-Landmark (FBL) is published by IMR Press from Volume 26 Issue 5 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with Frontiers in Bioscience.

The role of transforming growth factor-beta in primary brain tumors
Show Less
1 Department of Medicine, Division of Neurology, Duke University Medical Center, Durham, NC 27710, USA

Academic Editor: Van Meir

Front. Biosci. (Landmark Ed) 2003, 8(5), 245–260;
Published: 1 January 2003
(This article belongs to the Special Issue Encyclopedia of neuro-oncology)

Dramatic therapeutic benefits of targeting specific signal transduction pathways in some cancers have pushed rational molecular targeting to the forefront of cutting-edge cancer therapy. The identification and targeting of pathways critical to the phenotype of cancers offers new hope in the treatment of many patients. Transforming growth factor beta (TGF-beta) is a multifunctional cytokine that is frequently expressed in multiple types of malignant brain tumors. TGF-beta exerts a complex set of effects in cancers with an early tumor suppressive effect through growth inhibition but later effects in cancer development that are tumorigenic - including increased tumor cell motility and invasion, induction of angiogenesis, and immune suppression. Early preclinical and clinical studies have shown promise of anti-TGF-beta strategies in the treatment of malignant gliomas suggesting TGF-beta may be a potential new therapeutic target in neuro-oncology.

Back to top